Literature DB >> 11820459

Interaction of amorphous calcium phosphate with fibrin in vitro causes decreased fibrinolysis and altered protease profiles: implications for atherosclerotic disease.

G S Makowski1, M L Ramsby.   

Abstract

Previously, we demonstrated that amorphous calcium phosphate (ACP), chemical precursor to apatite, strongly interacted with fibrin and facilitated binding of matrix metalloproteinase (MMP)-9, a type IV collagenase. Plasmin-dependent fibrinolysis resulted in coordinate MMP-9 activation. Here we report on the effect(s) of ACP on fibrin degradation and binding of endogenous plasma proteases. Electrophoresis (8.5% SDS-PAGE) revealed that fibrin formed in the presence of ACP demonstrated characteristic gamma-gamma dimers (90-kDa) and beta-monomers (55-kDa), but resisted spontaneous fibrinolysis (72 h, 37 degrees C) or degradation by plasminogen activators (uPA, tPA). Casein zymography revealed an ACP-dependent decrease in fibrin binding of a low molecular weight (Mw) protease triplet (47-, 43-, 42-kDa) and increased fibrin binding of two high Mw proteases (94- and 84-kDa). The low Mw triplet also possessed gelatinolytic activity, but was not an MMP since 1,10-phenanthroline was ineffective as an inhibitor. Fibrin-binding proteases were inhibited to some degree by the serine protease inhibitor aprotinin. Competition/dissociation experiments with epsilon-aminocaproic acid revealed that the low Mw triplet lacked kringle regions whereas the 94- and 84-kDa proteases were tentatively identified and glu-/lys-plasmin(ogen)s. The triplet may, however, represent one or more kringle deficient mini-plasminogen(s), since electrophoretic mobility and substrate specificity was similar to elastase-generated mini-plasminogen. To explore these findings in a clinically relevant setting, a series of plasma samples was collected from a patient with unstable angina prior to, during, and post coronary artery bypass graft (CABG) surgery. Fibrin formed from plasma collected during and immediately post CABG was associated with increased fibrinolytic capacity and enhanced binding of a) MMP-9, b) the low Mw protease triplet (described above), and c) PA (as putative 110-kDa tPA:PAI-1 complex). The relevance of these findings to pathologic calcification of atherosclerotic plaques is discussed.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11820459     DOI: 10.1023/a:1012831900153

Source DB:  PubMed          Journal:  Inflammation        ISSN: 0360-3997            Impact factor:   4.092


  40 in total

Review 1.  Fibrin polymerization and its regulatory role in hemostasis.

Authors:  M W Mosesson
Journal:  J Lab Clin Med       Date:  1990-07

2.  Calibrating gelatin zymograms with human gelatinase standards.

Authors:  G S Makowski; M L Ramsby
Journal:  Anal Biochem       Date:  1996-05-01       Impact factor: 3.365

3.  Hypercoagulability and hypofibrinolysis in primary osteoarthritis.

Authors:  P A Cheras; A N Whitaker; E A Blackwell; T J Sinton; M D Chapman; K A Peacock
Journal:  Clin Orthop Relat Res       Date:  1997-01       Impact factor: 4.176

4.  Occlusion of plasma proteins by human fibrin: studies using trace-labelled proteins.

Authors:  E Regoeczi
Journal:  Br J Haematol       Date:  1968-03       Impact factor: 6.998

5.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

6.  Effect of cardiopulmonary bypass on systemic release of neutrophil elastase and tumor necrosis factor.

Authors:  J Butler; D Parker; R Pillai; S Westaby; D J Shale; G M Rocker
Journal:  J Thorac Cardiovasc Surg       Date:  1993-01       Impact factor: 5.209

7.  Noncollagenous bone matrix proteins, calcification, and thrombosis in carotid artery atherosclerosis.

Authors:  A Bini; K G Mann; B J Kudryk; F J Schoen
Journal:  Arterioscler Thromb Vasc Biol       Date:  1999-08       Impact factor: 8.311

8.  Matrix metalloproteinase inhibitor prevents acute lung injury after cardiopulmonary bypass.

Authors:  D E Carney; C J Lutz; A L Picone; L A Gatto; N S Ramamurthy; L M Golub; S R Simon; B Searles; A Paskanik; K Snyder; C Finck; H J Schiller; G F Nieman
Journal:  Circulation       Date:  1999-07-27       Impact factor: 29.690

9.  Enhanced fibrinolytic activity during cardiopulmonary bypass in open-heart surgery in man is caused by extrinsic (tissue-type) plasminogen activator.

Authors:  J Stibbe; C Kluft; E J Brommer; M Gomes; D S de Jong; J Nauta
Journal:  Eur J Clin Invest       Date:  1984-10       Impact factor: 4.686

10.  Intra- and postoperative fibrinolysis in patients undergoing cardiopulmonary bypass surgery.

Authors:  J A Páramo; J Rifón; R Llorens; J Casares; M J Paloma; E Rocha
Journal:  Haemostasis       Date:  1991
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.